VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be releasing its financial and operating report for the first quarter 2021, the period ended June 30, 2021, on Aug. 12. 2021. The company also announced that it will host a conference call discussing the report on the same day, Aug. 12, beginning at 2 p.m. PT (5 p.m. ET). Company executives, including VistaGen CEO Shawn Singh, will also provide a business update during the call, including the discussion of target milestones and future goals. The call will also be available on a live audio webcast. Interested participants in the United States can call 1-800-935-5014 and use the conference ID 21996610; international participants can call 1-212-231-2920 and use the same ID. Those calling in are encouraged to call in at least 10 minutes before the call begins. A replay of the call will be available later that day. To access the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll applies); use the replay PIN 21996610.
To view the webcast, visit https://ibn.fm/ncs2h
To view the full press release, visit https://ibn.fm/83M13
About VistaGen Therapeutics Inc.
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.